EUCTR2006-002216-10-NL进行中（未招募）不适用
A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexate - RACER
Procter & Gamble Pharmaceuticals0 个研究点目标入组 270 人开始时间: 2006年11月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who meet all of the following criteria are eligible for participation in the study:
- •a. Men and women, 18 to 70 years of age, inclusive, at screening;
- •b. Who meet ACR criteria for RA, with a documented diagnosis of RA for at least 6 months;
- •c. Whose functional capacity is class I, II, or III according to the revised criteria of the ACR (Appendix 6);
- •d. Who have active disease despite treatment with MTX before washout of any DMARDs other than MTX. Active disease for this study will be defined as follows:
- •- At least 6 swollen joints and 6 tender joints; AND,
- •- At least one of the following 3 criteria must be present:
- •ESR of at least 28 mm/hour
- •Elevated CRP
- •Morning stiffness lasting at least 45 minutes;
- •d. Who have been treated with MTX for at least 24 weeks. The dose of MTX must be stable for at least 8 weeks, at 15-20 mg/week, or at 10 mg/week if that is the maximal tolerated dose, before starting study medication;
- •e. If female, must be (as documented in the patient notes):
- •- Post menopausal (at least 1 year without spontaneous menses), or
- •- Surgically sterile (if by tubal ligation, must have been performed at least 3 months before entry into the study), or
- •- Using acceptable contraception (e.g., oral, intramuscular, or implanted hormonal contraception, intra-uterine device) for at least 3 months prior to randomization and for the duration of the study including the follow-up period, in conjunction with a barrier method (e.g., condom and spermicide, diaphragm and spermicide) for the duration of the study and during the follow-up period;
- •NOTE: All contraception precautions for MTX must be followed.
- •f. If sexually-active male, must be surgically sterile (e.g., non-reversed vasectomy with confirmed azoospermia) or use condom during the study and during the follow-up period;
- •NOTE: All contraception precautions for MTX must be followed.
- •g. Who are willing and able to participate in the study and provide signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Active or latent tuberculous infection as defined as: history of tuberculosis (TB) OR Chest X ray suggestive of former or current tuberculous infection OR Positive tuberculin skin test with purified protein derivative of tuberculin (PPD) equal to or more than 5 mm in a patient without history of vaccination with bacillus Calmette-Guérin (BCG) OR In Europe, vaccination with BCG and positive PPD equal to or more than 8 mm OR In Europe, vaccination with BCG and positive PPD equal to or more than 5 mm but =8 mm and any of the following risk factors: silicosis, residents and employees of high-risk congregate settings, weight loss more than10% of ideal body weight, gastrectomy, jejunoileal bypass
- •- Active listeriosis
- •- History of episode of infection requiring hospitalization within 30 days before screening or episode of infection requiring IV antibiotics within 30 days before sceening or current active infection
- •- History of chronic or recurrent infections, or immunodeficiency
- •- Indwelling catheters
- •- Bronchiectasis
- •- History of uveitis or other inflammatory eye disease
- •- Autoimmune diseases other than RA [MCTD, seronegative spondyloarthropathy, SLE, UCTD, psoriatic arthritis, sarcoidosis, etc.], except Sjogren’s syndrome secondary to RA
- •- Chronic liver diseases, serologic evidence for infection with hep B or hep C
- •- History of alcohol or drug abuse
- •- Abnormal hepatic and renal functions; patients with known elevations of transaminases greater than 1.2 times ULN on 2 or more occasions in the 6 months before screening
- •- Platelets <100 x 109/L
- •- Abnormal WBC and/or significant abnormalities in other complete blood count (CBC) values. Hemoglobin (Hgb) <10 mg/dL
- •- Joint surgery within 2 months of screening
- •- History of lymphoma, leukemia, or lymphoproliferative disorders
- •- History of other malignancies other than treated basal cell carcinoma of the skin
- •- History of demyelinating diseases
- •- History of heart failure, NYHA class III or IV
- •- Pregnant or lactating women, or women who plan to become pregnant
- •- Personal or family history of prolonged QT syndromes.
- •- Other risk factors for torsade de pointes (TdP)
- •- Hypokalemia, hypomagnesemia, or hypocalcemia;
- •- Drugs known to cause prolongation of QT interval (must be off for at least 5 half-lives to be enrolled)
- •- Demonstrated likelihood not to comply with protocol requirements
- •- Current participation in another clinical trial involving active intervention
- •- Known allergy to components of the study medication
- •- History of efficacy failure with etanercept, infliximab, adalimumab, anakinra, and abatacept
- •- History of treatment with B cell depleting therapies and immunoadsorption
- •- History of treatment with p-38 MAP kinase inhibitors
- •- History of treatment with cyclosporine, cyclophosphamide, or other alkylating agents
- •- Other diseases requiring immunosuppressive therapy
- •- Treatment with leflunomide within 6 months prior to study entry
- •- Intra-articular or intramuscular steroids within 4 weeks before screening
- •- Change in NSAID and/or corticosteroid doses within 30 days prior to entry into the study (Day 1 of the washout period)
- •- Treatment with any experimental/investigational therapy within the last 2 months for chemical and 6 months (from screening date) for biologic drugs
- •- Use of the following inducers of CYP 3A4 (carbamazepine, phenobarbital, phenytoin, St John's Wort and troglitazone) or inhibitors of CYP 3A4 (diltiazem, fluvoxamine, grapefruit juice, itraconazole, ketoconazole, mibefr
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexate - RACERMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2006-002216-10-HUProcter & Gamble Pharmaceuticals270
进行中（未招募）
不适用
A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexate - RACERRheumatoid ArthritisEUCTR2006-002216-10-CZProcter & Gamble Pharmaceuticals270
尚未招募
2 期
A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexategewrichtsaandoeningenrheumatoid arthritisNL-OMON30408Procter & Gamble30
进行中（未招募）
1 期
A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexate - RACERRheumatoid ArthritisEUCTR2006-002216-10-GBProcter & Gamble Pharmaceuticals270
进行中（未招募）
1 期
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS)Focal segmental glomerulosclerosis (FSGS)MedDRA version: 21.1Level: PTClassification code 10067757Term: Focal segmental glomerulosclerosisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2016-005141-23-PTTravere Therapeutics Inc.300